After brain ischemia, significant amounts of adenosine 5 0 -triphosphate are released or leaked from damaged cells, thus activating purinergic receptors in the central nervous system. A number of P2X/ P2Y receptors have been implicated in ischemic conditions, but to date the P2Y 1 receptor (P2Y 1 R) has not been implicated in cerebral ischemia. In this study, we found that the astrocytic P2Y 1 R, via phosphorylated-RelA (p-RelA), has a negative effect during cerebral ischemia/reperfusion. Intracerebroventricular administration of the P2Y 1 R agonist, MRS 2365, led to an increase in cerebral infarct volume 72 hours after transient middle cerebral artery occlusion (tMCAO). Administration of the P2Y 1 R antagonist, MRS 2179, significantly decreased infarct volume and led to recovered motor coordination. The effects of MRS 2179 occurred within 24 hours of tMCAO, and also markedly reduced the expression of p-RelA and interleukin-6, tumor necrosis factor-a, monocyte chemotactic protein-1/chemokine (C-C motif) ligand 2 (CCL2), and interferon-inducible protein-10/chemokine (C-X-C motif) ligand 10 (CXCL10) mRNA. P2Y 1 R and p-RelA were colocalized in glial fibrillary acidic protein-positive astrocytes, and an increase in infarct volume after MRS 2365 treatment was inhibited by the nuclear factor (NF)-jB inhibitor ammonium pyrrolidine dithiocarbamate. These results provide evidence that the P2Y 1 R expressed in cortical astrocytes may help regulate the cytokine/chemokine response after tMCAO/reperfusion through a p-RelA-mediated NF-jB pathway.
Introduction
Reactive astrocytes and microglia contribute to various disorders of the central nervous system (CNS), such as Alzheimer disease, multiple sclerosis, Parkinson disease, neuropathic pain, and stroke. Following cerebral ischemia, astrocytes and microglia become activated. On activation, these reactive astrocytes increase in number and form a wall-like boundary zone (the glial limitans) that surrounds the ischemic region called the penumbra (Stoll et al, 1998) , which is where much of the reperfusion injury and delayed cell death occur.
Both in vivo and in vitro studies have shown that significant amounts of adenosine 5 0 -triphosphate (ATP) are released or leaked from damaged neurons or glial cells under conditions of cerebral ischemia. Extracellular ATP functions through the purinergic receptor family, which consists of ionotrophic P2Xs and G protein-coupled P2Ys. Several P2 receptors have been implicated in cerebral ischemic brain damage. For instance, the P2X1, P2X2, P2X4, P2X7, and P2Y 1 receptors (P2Y 1 Rs) are upregulated in neurons or glial cells in various brain regions after ischemia (Tu and Wang, 2009) , and a significant reduction in infarct volume has been observed following treatment with pyridoxal-phosphate-6azophenyl-2 0 ,4 0 -disulfonic acid, a P2 receptor antagonist (Lammer et al, 2006) . Thus, P2 receptors are thought to have a key role in the pathophysiology of cerebral ischemia.
Nuclear factor-k-light-chain enhancer of activated B cells (NF-kB) is expressed in many cell types in the CNS and is activated by various stimuli in focal ischemia, for example, glutamate, interleukin (IL)-1, tumor necrosis factor-a (TNF-a), and reactive oxygen species (O'Neill and Kaltschmidt, 1997) . The NF-kB consists of five subunits: NF-kB1/p50, NF-kB2/p52, RelA/p65, RelB, and c-Rel (Hayden and Ghosh, 2004; O'Neill and Kaltschmidt, 1997) . These subunits can form homodimers and heterodimers and induce the transcription of many genes involved in the pathogenesis of cerebral ischemia, such as IL-6, TNF-a, intercellular adhesion molecules, inducible nitric oxide synthase, and cyclooxygenase-2 (O'Neill and Kaltschmidt, 1997) . In focal cerebral ischemia, an increase in the transcriptional activity of NF-kB is critical for ischemic damage and cell death (Schneider et al, 1999; Zhang et al, 2005) .
In this study, we focused on the role of the P2Y 1 R and phosphorylated-RelA (p-RelA) in the pathophysiology of cerebral ischemia. The P2Y 1 R, a Gq/G11 protein-coupled receptor, is widely distributed throughout the CNS, and astrocytic P2Y 1 R is involved in the secretion of glutamate and several proinflammatory cytokines (Fujita et al, 2009; Sun et al, 2008) . The P2Y 1 R has been shown to be involved in cardiac ischemia and Alzheimer disease (Moore et al, 2000; Olivecrona et al, 2007) ; however, the role of the P2Y 1 R in ischemic brain injury remains unclear. Here, we report that the P2Y 1 R and p-RelA are localized in astrocytes and are key mediators of brain damage during ischemia and reperfusion injury.
Materials and methods

Animals
All experimental procedures were performed in accordance with institutional guidelines at Kyushu University regarding the care and use of animals. Male Sprague-Dawley rats (8 to 12 weeks old, 270 to 320 g) were obtained from Kyudo Co., Ltd. (Tosu, Japan). The rats were housed in groups of four per cage at a temperature of 221C ± 11C with a 12-hour light-dark cycle (lights on between 08:30 and 20:30 hours), and had ad libitum access to food and water.
Transient Middle Cerebral Artery Occlusion
Transient middle cerebral artery occlusion (tMCAO) was performed using a standard intraluminal procedure as described previously (Harada et al, 2005) . The rats were anesthetized by inhalation of 2% (v/v) isoflurane in 60% (v/v) oxygen air. Body temperature was maintained at 37.01C±0.21C using a heating pad (ATC-101B, Unique Medical, Tokyo, Japan). A rectangular thin probe (LP-CM, Unique Medical) for the laser Doppler flowmetry was inserted under the temporal muscle over the temporal cortex as previously reported (Harada et al, 2005) . A silicon-coated 30 mm 4-0 nylon monofilament was inserted into the internal carotid artery through a small incision of the right common carotid artery. The rats were then allowed to recover from general anesthesia. Following tMCAO for 30 or 60 minutes, the cervical incision was reopened under brief general anesthesia to allow reperfusion of the MCA. The tMCAO was confirmed by measuring regional cerebral blood flow over the MCA territory using laser Doppler flowmetry (ALF21, Advance Co., Inc., Tokyo, Japan). In the sham group, rats were treated by using the same approach as that of tMCAO, with the exception of insertion of the silicon-coated 30 mm 4-0 nylon monofilament and reperfusion steps.
Intracerebroventricular Drug Administration
The intracerebroventricular drug administration experiments were performed according to the following protocol. The rats were anesthetized by inhalation of 2% (v/v) isoflurane and mounted onto a stereotaxic apparatus (David Kopf Instruments, Tujunga, CA, USA). The skull was exposed and a hole was drilled to place a 22-gauge guide cannula (VIDTEC, Fukuoka, Japan) into the lateral ventricle (Bregma coordinates: 0.8 mm posterior, 1.4 mm right lateral, 3.5 mm ventral). The rats were randomized and administrated with either 3 mL of [[(1R,2R,3S,4R,5S)-4-[6-Amino-2-(methylthio)-9H-purin-9-yl]-2,3-dihydroxybicyclo[3.1.0]hex-1-yl]methyl] diphosphoric acid mono ester trisodium salt (MRS 2365; Tocris Bioscience, Bristol, UK), 2 0 -Deoxy-N 6 -methyladenosine 3 0 ,5 0 -bisphosphate tetrasodium salt (MRS 2179; Tocris Bioscience), adenosine 3 0 -phosphate 5 0 -phosphosulfate lithium salt hydrate (A3P5PS; Sigma, St Louis, MO, USA), (1R*,2S*)-4-[2-Chloro-6-(methylamineo)-9H-purin-9-yl]-2-(phosphonooxy)bicyclo[3.1.0]hexane-1methanol dihydrogen phosphate ester diammonium salt (MRS 2279; Tocris Bioscience), and ammonium pyrrolidine dithiocarbamate (APDC; Wako, Osaka, Japan), MRS 2179 + APDC, MRS 2365 + APDC. A cohort of animals (referred to as the vehicle) received an intracerebroventricular injection of artificial cerebrospinal fluid. Within the protocol there were six time points at which the animals received the intracerebroventricular drug administration: 15 minutes before MCA occlusion, and 12, 24, 36, 48, and 60 hours after cerebral blood flow reperfusion. The rats were treated with the compounds twice daily. Within these six time points, three were considered 'early': 15 minutes before MCA occlusion, 12 and 24 hours after reperfusion; and three were considered 'late': 36, 48, and 60 hours after reperfusion. For the samples to be analyzed 24 hours after tMCAO by immunohistochemistry, Western blot, or real-time quantitative reverse transcriptase polymerase chain reaction, the drugs were administrated at two time points: 15 minutes before MCA occlusion and 12 hours after reperfusion. Verification of cannula placement was made by visual observation following dissection of the rat brain. Only the samples with correct cannula placement were included for analysis.
Analysis of Cerebral Infarct Volume
The rats were anesthetized with pentobarbital (100 mg/kg, intraperitoneally) 72 hours after reperfusion of the MCA.
The brains were removed and the forebrain was sliced into 2-mm-thick coronal sections. The sections were stained with 2% (w/v) 2,3,5-triphenyltetrazolium at 371C for 30 minutes and fixed in 20% (w/v) paraformaldehyde. The stained slices were photographed using a complementary metal oxide semiconductor camera with a squared scale to calculate the area of the infarct. Infarct size was analyzed using Image J 1.42q software (National Institutes of Health, Bethesda, MD, USA) and compared with the ipsilateral hemisphere. Total infract volume (mm 3 ) was determined by multiplying the infarct area by slice thickness (2 mm). Animals with large hematomas in the brain or those that exhibited no infarct were omitted from further analyses.
Rotarod Test
Motor coordination was performed using the KN-75 rotarod apparatus (Natsume, Tokyo, Japan). The rotating speed proportionally increased from 3 to 20 r.p.m. in 0 to 300 seconds. Rotarod test was performed just before drug treatments at 24, 48, and 72 hours after tMCAO to rule out acute drug effects.
Immunohistochemistry
The rats were anesthetized with pentobarbital (100 mg/kg, intraperitoneally) and perfused transcardially with 4% (w/v) paraformaldehyde. Brain sections were obtained, postfixed, and placed in 30% (w/v) sucrose solution for 24 hours at 41C. The sections (30 mm) were incubated in blocking solution (3% (v/v) normal goat serum/0.3% (v/v) Triton X-100/phosphate-buffered saline) for 2 hours at room temperature, followed by incubation with primary antibodies: mouse antiglial fibrillary acidic protein (anti-GFAP) antibody (1:500; Chemicon, Temecula, CA, USA), mouse antiionized calcium-binding adaptor molecule 1 (anti-Iba1) antibody (1:2,000; Wako), mouse anti-CD11b (anti-OX42) antibody (1:1,000; Serotec, Kidlington, UK), mouse antineuronal nuclei antibody (1:200; Chemicon), rabbit anti-P2Y 1 R antibody (1:1,000; Alomone, Jerusalem, Israel), or rabbit antiphospho-NF-kB p65 (Ser536; anti-p-RelA) antibody (1:100; Cell Signaling, Beverly, MA, USA) for 48 hours at 41C. The sections were washed and incubated with anti-rabbit immunoglobulin G-conjugated Alexa Fluor 488, anti-mouse immunoglobulin G-conjugated Alexa Fluor 488, or anti-mouse immunoglobulin Gconjugated Alexa Fluor 546 (1:1,000; Molecular Probes, Invitrogen, Carlsbad, CA, USA) for 3 hours at room temperature. The brain sections were analyzed by confocal microscopy (LSM510; Zeiss, Oberkochen, Germany). The intensity of Iba1 and OX42 immunoreactivity was analyzed using the Photoshop CS3 software (Adobe, San Jose, CA, USA) and the mean of total fluorescent intensity in the ischemic hemisphere was digitalized.
Western Blotting
The right hemisphere of the brain (B±1.00 mm from the Bregma) was removed, and total protein extraction was performed according to a previously described method (Hasegawa et al, 2009 ). Samples were separated on a 10% (v/v) polyacrylamide gel, and the protein was transferred onto a polyvinylidene difluoride membrane. The membranes were blocked in Blocking One-P (Nacalai tesque, Kyoto, Japan), incubated with anti-p-RelA antibody (1:1,000) overnight at 41C and then incubated with horseradish peroxidase-conjugated anti-rabbit immunoglobulin G antibody (1:1,000; Amersham Biosciences, Little Chalfont, UK). Protein was detected using the chemiluminescence method (ECL system; Amersham Biosciences).
Real-Time Quantitative Reverse Transcriptase Polymerase Chain Reaction
Coronal brain sections (B ± 1.00 mm from the Bregma) were removed, and total RNA was prepared with the TRIsure (Bioline, London, UK) and RNeasy Mini total RNA Preparation Kit (Qiagen, Dusseldorf, Germany), in accordance with the methods described previously (Fujita et al, 2009) . Reverse transcriptase polymerase chain reaction amplification and real-time detection were performed using an ABI PRISM 7500 (Applied Biosystems, Carlsbad, CA, USA). All expression values were normalized by the expression values of 18S ribosomal RNA. The TaqMan probe and the forward and reverse primers used in this study were designed according to Table 1 . Ribosomal RNA was measured using TaqMan Ribosomal RNA Control Reagents (P/N 4308329; Applied Biosystems).
Statistics
Data are expressed as the mean with s.e.m. Statistical analyses of the results were conducted with one-way analysis of variance, one-way repeated analysis of variance, or two-way analysis of variance with a post hoc test (Tukey multiple comparison test). Statistical significance was set at a P value < 0.05. Table 2 shows the values for regional cerebral blood flow over the MCA territory in rats that underwent intracerebroventricular administration with the vehicle or the different compounds before or after common carotid artery occlusion, after MCA occlusion, or after reperfusion. These findings did not show any significant differences in the rate of change of regional cerebral blood flow among any of the groups.
Results
Regional Cerebral Blood Flow
P2Y 1 R Expression in the Central Nervous System
Localization of the P2Y 1 R in the rat brain was determined by fluorescent immunohistochemistry for the P2Y 1 R and several cell-type-specific markers. The P2Y 1 R only colocalized with GFAP (an astrocyte marker) but did not colocalize with the microglial marker, OX42, or the neuronal marker, neuronal nuclei. This cell-specific localization did not alter between the sham surgery and tMCAO (at 24, 48, or 72 hours after reperfusion) groups ( Figure 1A ). In the penumbra region, the P2Y 1 R-positive area correlated with the GFAP-positive area; however, there was no P2Y 1 R signal in the Iba1-positive area, which was likely the ischemic core region ( Figure 1B) . These results indicate that astrocytes express P2Y 1 R in the intact and penumbra region. Moreover, we measured GFAP, Iba1, and P2Y 1 R mRNA expression following ischemia. Although GFAP and Iba1 mRNA expression levels significantly increased after 24 to 72 hours of tMCAO ( Figures 1C and 1D) , there was no significant change in P2Y 1 R mRNA expression ( Figure 1E ). After cerebral ischemia and reperfusion, cerebral infarct volume increased after reperfusion. In fact, infarct volume significantly increased during 24 to 72 hours after tMCAO ( Figures 1F and 1G) .
Effect of the P2Y 1 R Agonist and Antagonists on Infarct Volume and Motor Coordination
We measured cerebral infarct volume after 72 hours of tMCAO in rats that were intracerebroventricularly administered different compounds (twice daily for 3 days). The administration of 10 nmol MRS 2365 significantly induced an increase in infarct volume in the MCA 30-minute occlusion model, but there was no change in infarct volume compared with the vehicle group in the MCA 60-minute occlusion model (Figures 2A-2C) . Moreover, the administration of MRS 2179, A3P5PS, and MRS 2279 significantly reduced infarct volume in a dosedependent manner (Figures 2D, 2E, 2G, and 2H) . The decrease observed with 3 nmol MRS 2179 was B63.8% (1,350±166 to 488±48 mm 3 , n = 6). In addition, these antagonists significantly inhibited motor coordination deficits after tMCAO ( Figures 2F  and 2I ). We also investigated the period of time during which the P2Y 1 R antagonist had a cerebroprotective effect. The infarct volume in the rats that were admininstered an intracerebroventricular injection of 3 nmol MRS 2179 were compared between the early group (15 minutes before MCA occlusion and 12 and 24 hours after reperfusion) and the late group (36, 48, and 60 hours after reperfusion). Although in the early group there was reduced infarct volume relative to the vehicle-treated rats, there was no cerebroprotection in the late group relative to the vehicle-treated rats ( Figures 2J and 2K ).
mRNA Expression of Cytokines/Chemokines Following Occlusion
In this study, the mRNA expression of several cytokines/chemokines was markedly upregulated 24 hours after tMCAO. In the cortex, an increase in IL-6, TNF-a, monocyte chemotactic protein-1 (MCP-1)/chemokine (C-C motif) ligand 2 (CCL2), and interferon-inducible protein-10 (IP-10)/chemokine (C-X-C motif) ligand 10 (CXCL10) mRNA was significantly suppressed by 3 nmol MRS 2179 ( Figure  3A) . In contrast, the P2Y 1 R did not appear to be involved in the transcription of macrophage inflammatory protein-1a/CCL3, macrophage inflammatory protein-2/CXCL2, and MCP-5/CCL12 (data not shown). These results suggest that the P2Y 1 R critically contributes to transcriptional upregulation of several cytokines/chemokines under ischemic conditions.
Microglial Activation and/or Macrophage Accumulation
As microglia and macrophages are considered to be major sources of proinflammatory cytokines and chemokines, we used immunohistochemistry to assess whether the administration of 3 nmol MRS 2179 suppressed the activation of microglia and macrophages. The activation of resident microglia and infiltrated macrophages was evaluated by measuring Iba1 and OX42 immunoreactivity. We found that the intensity of Iba1 and OX42 immunoreactivity staining in the tMCAO rats was significantly lower in the MRS 2179 administration group ( Figures  3B and 3C) .
Expression of Phosphorylated-RelA
In the tMCAO rat brain, the p-RelA protein gradually increased 6 to 24 hours after reperfusion ( Figure 4A) . Notably, p-RelA colocalized with GFAP, but not with OX42 or neuronal nuclei ( Figure 4C ). As this localization was similar to that of the P2Y 1 R (see Figure 1A) , we assessed the effect of 3 nmol MRS 2179 on p-RelA expression after 24 hours of tMCAO. MRS 2179 administration significantly suppressed the increase in p-RelA levels ( Figure 4B ). Thus, these results suggest that RelA is phosphorylated and activated by P2Y 1 R signaling in astrocytes.
Inhibition of Nuclear Factor-jB Activation
We investigated the effect of APDC, a NF-kB inhibitor, on tMCAO. Cerebral infarct volume was significantly reduced following 30 nmol APDC administration ( Figures 4D and 4E ) after 72 hours of tMCAO. The amount of decrease with APDC was B43.3% (1,343±116 to 761±70 mm 3 , n = 6). Moreover, APDC reduced motor coordination deficits ( Figure 4F ) and suppressed the upregulation of cytokine/chemokine mRNA levels ( Figure 4G ) after tMCAO. These results correlate well with the results obtained after MRS 2179 administration. Finally, we investigated the effect of combining APDC with MRS 2365 and MRS 2179. In this case, cotreatment with 3 nmol MRS 2179 and 30 nmol APDC resulted in a marked reduction in infarct volume after 72 hours tMCAO (Figures 5A and 5B) . The change of decrease with MRS 2179 and APDC was B58.0% (1,210 ± 65 to 508±49 mm 3 , n = 6), and there was no additive effect with the two compounds relative to using each alone. Moreover, the increase in infarct volume observed after 10 nmol MRS 2365 treatment in the MCA 30-minute occlusion model (see Figures 2A  and 2B ) was significantly suppressed with APDC cotreatment (Figures 5C and 5D ).
Discussion
Adenosine 5 0 -triphosphate contributes to various CNS diseases including stroke. Following cerebral ischemia, intracellular ATP vanishes and acute necrosis occurs because the supply of oxygen and glucose is interrupted. In this period, ATP is released or leaked by damaged or dying cells (Melani et al, 2005) . After cerebral blood reperfusion, ATP is resynthesized as the supply of oxygen and glucose to the site is reestablished. It is considered that damaged cells, reactive astrocytes, and neurons release extracellular ATP after reperfusion. Although intracellular ATP behaves as a 'molecular unit of currency' for intracellular energy, in contrast, extracellular ATP has a role as a transmitter molecule. Extracellular ATP functions through the purinergic (P2) receptors presented on the cell membrane and is involved in purinergic signaling in the pathology of ischemic damage. The purinergic receptors, P2X2, P2X4, and P2X7, are upregulated in microglia and the P2Y 1 R is localized to astrocytes. Previous work has found that, although the broad-spectrum P2 receptor antagonist, pyridoxal-phosphate-6-azophenyl-2 0 ,4 0 -disulfonic acid, is cerebroprotective, the P2X7R antagonist, benzoyl-ATP, can significantly exacerbate ischemic damage (Suzuki et al, 2004) . This type of research underscores the importance of understanding the P2 receptor subtypes that ATP functions on.
In previous studies, hippocampal and retinal pyramidal cells, cerebellar Purkinje cells, and glial cells, grouped together as astrocytes, have been found to express P2Y 1 R (Moran-Jimenez and Matute, 2000) . In addition, in vitro studies have also confirmed P2Y 1 R expression in microglia (Ballerini et al, 2005; De Simone et al, 2010) . However, in this report, we have shown that the P2Y 1 R is expressed on astrocytes before and after focal cerebral ischemia, using an in vivo model. Although it is possible that the other cell types may have limited P2Y 1 R expression, our data suggest that P2Y 1 R expression is mainly restricted to astrocytes. Interestingly, follow-ing tMCAO, the P2Y 1 R accumulated in the penumbra, as did GFAP. This observation suggests that the astrocytic P2Y 1 R may contribute to the protective function of the penumbra region. Following ischemia and reperfusion, GFAP and Iba1 mRNA expression levels were significantly increased but there was no increase in the expression of P2Y 1 R mRNA. Astrocytes perished in the ischemic core and increased in penumbra, thus making the determination of absolute number of astrocytes difficult.
After ischemia and reperfusion, despite cerebral blood reperfusion, the development of cerebral injury was observed at the 24-to 72-hour time point. We have previously shown that P2Y 1 R expression in cultured astrocytes is actively involved in the protection against hydrogen peroxide, an reactive oxygen species generated in ischemic stroke. Furthermore, neuroprotection is induced by astrocytic P2Y 1 R stimulation via IL-6 release in hippocampal astrocyte-neuronal cocultures (Fujita et al, 2009 ). These studies suggest that stimulation of P2Y 1 R signaling enhances protection from ischemia/reperfusion injury. However, in the present study, MRS 2365 markedly promoted an increase in infarct volume in the MCA 30-minute occlusion model. In the MCA 60-minute occlusion model, MRS 2365 did not worsen cerebral damage. A possible explanation for this is that the cerebral infarct volume itself might be too large, or that the concentration of ATP might be too high, which dampens the effect of the P2Y 1 R agonist. However, significant cerebroprotection was observed with A3P5PS, MRS 2279, and MRS 2179, which allowed for the maintenance of motor coordination following tMCAO. The P2Y 1 R agonist, 2-methylthio-ADP, has been reported to induce apoptosis by activating the human recombinant P2Y 1 R heterologously expressed in the 1321N1 astrocytoma cell line (Sellers et al, 2001) . Thus, the P2Y 1 R appears to possess a dual role in cell life and death, and its function may be dependent on the concentration and timing of ATP release, the extent of damage, and the influence of other cells. A recent study showed the involvement of the P2Y 1 R in cerebral ischemia, whereby the P2Y 1 R expressed on astrocytes enhance the expression of GFAP and the glial cell line-derived neurotrophic factor through the Janus kinase 2 (JAK2)/ signal transducer and activator of transcription 3 (STAT3) and phosphoinositide 3 kinase (PI3K)/ Akt/cAMP response element binding protein (CREB) signaling pathway (Sun et al, 2008) ; however, the present study is the first to suggest that ATP/P2Y 1 R signaling is the pathway responsible for the degeneration observed in focal cerebral ischemia. Moreover, administration of MRS 2179 at the three early times (15 minutes before MCA occlusion, and 12 and 24 hours after reperfusion), but not in the three late times (36, 48, and 60 hours after reperfusion), showed a reduction in the infarct volume. These data strongly (D) Images of 2,3,5-triphenyltetrazolium (TTC)-stained brain sections after 72 hours of tMCAO in APDC-treated rats. The damaged brain regions remained unstained. (E) Analysis of infarct volume in the subcortex (SC), cortex (Co), or total area in each group (n = 6 animals/group). (F) Motor coordination measured using the Rotarod test (n = 5 animals/group). (G) The relative expression of interleukin (IL)-6, tumor necrosis factor (TNF)-a, monocyte chemotactic protein-1 (MCP-1)/chemokine (C-C motif) ligand 2 (CCL2), and interferon-inducible protein (IP)-10/chemokine (C-X-C motif) ligand 10 (CXCL10) mRNA in the subcortex or cortex after 24 hours of tMCAO with or without APDC treatment. Data were normalized against the sham plus vehicle group (n = 5 animals/ group). All data in this figure showed mean with s.e.m. Statistical analysis was determined using one-way analysis of variance (ANOVA) (A, E), one-way repeated ANOVA (F), or two-way ANOVA (B, G) with Tukey test, *P < 0.05, **P < 0.01, ***P < 0.001, w P < 0.05, ww P < 0.01, www P < 0.001. Scale bars = 500 mm.
suggest that P2Y 1 R has a critical role during the 24 hours following cerebral damage after ischemia and reperfusion.
The P2Y 1 R is involved in modulating transcriptional activity in astrocytes (Fujita et al, 2009; Sun et al, 2008) . Our data, and that of previous studies (Minami et al, 2006) , have showed that IL-6, TNF-a, MCP-1/CCL2, and IP-10/CXCL10 mRNA expression is markedly upregulated in the 24 hours after tMCAO. These cytokines/chemokines are known to contribute not only to cerebral ischemia but also other neurodegenerative disorders, such as Alzheimer disease, multiple sclerosis, and acquired immune deficiency syndrome encephalopathy (Wang et al, 2002) . Previous investigations using a TNF-a neutralizing antibody or MCP-1/CCL2-deficient mice indicate that the depression of these cytokines/chemokines has a cerebroprotective effect (Barone et al, 1997; Hughes et al, 2002) . However, it has been reported that recombinant IL-6 reduces ischemic brain damage (Minami et al, 2006) , but this finding was not supported in IL-6-deficient mice (Clark et al, 2000) . Moreover, the inhibition of the IL-6 receptor resulted in an increase in infarct volume (Yamashita et al, 2005) . The conflicting roles of IL-6 indicate that more detailed studies are required. In this study, we showed that MRS 2179 significantly inhibited microglial and/or macrophage activation in the ischemic brain. The IP-10/CXCL10 is known as a migration factor for T cells and macrophages during cerebral ischemia (Wang et al, 1998) . Moreover, reactive microglia are thought to induce astrocyte activation via IL-1b or IL-18 release (Miyoshi et al, 2008) . In contrast, astrocytes contribute to the activation of microglia (Rohl and Sievers, 2005) . Because minocycline, which inhibits microglial activation in vivo (Raghavendra et al, 2003) , reduces infarct volume and brain atrophy (Yrjanheikki et al, 1999) , it is possible that cerebroprotection by MRS 2179 can be attributed to microglial and/or macrophage inactivation.
The main NF-kB subunits in the ischemic brain are NF-kB1/p50 and RelA/p65 (Zhang et al, 2005) . These subunits form heterodimeric complexes and classical pathways that require IkB kinases (Hayden and Ghosh, 2004) . There are various sites for serine phosphorylation on the RelA protein. For example, serine 536 is phosphorylated by IkB kinases after TNF stimulation, which increases the transcriptional efficacy of NF-kB (Hayden and Ghosh, 2004) . The NF-kB1:RelA complex has a pivotal role in the IL-6, TNF-a, and IP-10 response (Cui et al, 2006; O'Neill and Kaltschmidt, 1997) . We have showed that the p-RelA protein gradually increases 24 hours after tMCAO in astrocytes. The neuronal death by b-amyloid, ischemia, or status epilepticus are suppressed by NF-kB (Blondeau et al, 2001; Kaltschmidt et al, 1999) . In contrast, the NF-kB contributes to brain degeneration in ischemia, trauma, epilepsy, Alzheimer disease, Parkinson disease, and Huntington disease (Bethea et al, 1998; Kell, 2010; Nurmi et al, 2004) . Recently, the major cause of this dual cerebroprotection/degeneration effect was reported to be a NF-kB subtype-dependent pathway (Pizzi et al, 2009 ). c-Rel contributes to cerebroprotection and RelA induces neurodegeneration. Thus, an increase in the p-RelA protein may be induced by brain damage. This increase in p-RelA is completely blocked by MRS 2179. In addition, a similar result was also observed with APDC administration, with cerebroprotection and transcriptional repression. In addition, NF-kB1-deficient mice have been reported to show cerebral ischemic tolerance (Schneider et al, 1999) . In this study, there was no additive effect when using MRS 2179 and APDC in combination. Moreover, APDC significantly suppressed the increase of cerebral infarct volume induced by MRS 2365. These findings indicate that NF-kB has a role in cytokine/chemokine transcriptional activity and has a pivotal function during ischemic damage involving the P2Y 1 R.
In summary, we have showed that after cerebral ischemia, inhibition of the astrocytic P2Y 1 R results in cytokine/chemokine transcriptional suppression and cerebroprotection via NF-kB. Our findings open the door to new ideas for the development of strategies useful for the management of stroke and add to the current body of knowledge on the pathophysiology of focal cerebral ischemia.
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